Citigroup Reiterates Rentokil Initial plc

Citigroup reiterated a Buy recommendation for Rentokil Initial plc (RTO) on October 24, 2025, despite an average one-year price target of $28.02, which suggests a 4.39% downside from its latest closing price of $29.31. The company projects annual revenue of 6,094MM, representing a 10.12% increase, and a non-GAAP EPS of $0.28. Institutional sentiment remains bullish, indicated by a 0.68 put/call ratio, with total shares owned by institutions increasing by 6.46% in the last quarter, even as the number of reporting funds slightly decreased.

Analysis

Citigroup reiterated a "Buy" recommendation for Rentokil Initial (RTO) on October 24, 2025, signaling continued confidence in the company. However, the average one-year price target of $28.02 suggests a 4.39% downside from the current $29.31 closing price, indicating a potential near-term valuation concern despite the positive rating. The broad analyst price target range, from $19.17 to $38.60, underscores varied perspectives on RTO's intrinsic value.

The company's projected financials support a positive long-term view, with annual revenue expected to grow by 10.12% to $6,094MM. Non-GAAP EPS is forecast at $0.28, reflecting anticipated operational strength. These growth figures provide a fundamental basis for the analyst's "Buy" rating, focusing on future performance rather than immediate price target alignment.

Institutional investor activity indicates a net bullish sentiment, with total shares owned by institutions increasing by 6.46% over the last quarter. The average portfolio weight dedicated to RTO also rose by 6.02%, and the put/call ratio of 0.68 further confirms a bullish outlook. Notably, Oakmark International Fund significantly increased its RTO allocation by 954.46%, demonstrating strong conviction from a key institutional player.

Key Decisions for Investors

• Consider RTO for long-term growth portfolios, given projected 10.12% revenue growth and strong institutional accumulation despite the current price target suggesting a near-term downside.
• Monitor analyst price target revisions and the company's actual earnings performance against the $0.28 non-GAAP EPS projection, as these will be key drivers for future valuation.
• Evaluate the implications of the bullish 0.68 put/call ratio and increasing institutional ownership (6.46% rise in shares) as indicators of sustained market confidence.